Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 40 of 76 for:    nilotinib | cancer | Phase 2

Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01140568
Recruitment Status : Terminated (Sponsor contract was not renewed by mutual decision of sponsor and PI.)
First Posted : June 9, 2010
Last Update Posted : October 31, 2018
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
David Piccioni, M.D., Ph.D, University of California, San Diego

Tracking Information
First Submitted Date  ICMJE June 8, 2010
First Posted Date  ICMJE June 9, 2010
Last Update Posted Date October 31, 2018
Study Start Date  ICMJE May 2010
Actual Primary Completion Date October 5, 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 29, 2018)
To determine the efficacy of nilotinib in patients with recurrent malignant gliomas with PDGFR amplification as measured by 6-month progression-free survival. [ Time Frame: 6 months ]
Use of a survival status check and radiologic assessments (MRI or CT brain scans) every 6 months to measure disease progression.
Original Primary Outcome Measures  ICMJE
 (submitted: June 8, 2010)
To determine the efficacy of nilotinib in patients with recurrent malignant gliomas with PDGFR amplification as measured by 6-month progression-free survival. [ Time Frame: 6 months ]
Change History Complete list of historical versions of study NCT01140568 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: October 29, 2018)
  • To define the safety of nilotinib in this population based on frequency of adverse events leading to study discontinuation and number of significant laboratory abnormalities. [ Time Frame: 6 months ]
    Collection and assessment of side effect and abnormal lab assessment in relation to study participation.
  • To characterize the pharmacokinetics of nilotinib in this population by serum and cerebrospinal fluid (CSF) examination of drug and metabolites. [ Time Frame: 6 months ]
    Collection and assessment of serum and CSF to examine the nilotinib drug concentrations in the body.
Original Secondary Outcome Measures  ICMJE
 (submitted: June 8, 2010)
  • To define the safety of nilotinib in this population based on frequency of adverse events leading to study discontinuation and number of significant laboratory abnormalities. [ Time Frame: 6 months ]
  • To characterize the pharmacokinetics of nilotinib in this population by serum and cerebrospinal fluid (CSF) examination of drug and metabolites. [ Time Frame: 6 months ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas
Official Title  ICMJE A Phase II Study of PDGFR Kinase Inhibitor in Biomarker-Enriched Recurrent Malignant Gliomas
Brief Summary The purpose of this study is to determine the survival, disease response, and side effects of Tasigna® (nilotinib) in patients who have malignant gliomas and are positive for Platelet Derived Growth Factor Receptor (PDGFR) amplification. This study is designed to test the hypothesis that patients with malignant gliomas with PDGFR amplification are sensitive to PDGFR kinase inhibitors.
Detailed Description

Malignant gliomas (MG), including anaplastic gliomas (AG) and glioblastoma (GBM), are the most common primary brain tumor. Standard of care (surgery, radiotherapy, and temozolomide at initial diagnosis) results in a median survival of only 14 months. For patients with recurrent disease, conventional chemotherapy is generally ineffective with response rates <20%. Clearly there is need for improved treatments. Recent genome-wide studies have confirmed that GBM is a heterogeneous group of diseases that can be subclassified by shared genetic aberrations. The implication is that, in part, the underlying genetics may determine responsiveness to treatments and thus allow us to personalize therapy.

This is an, open-label, non-randomized, phase II study with oral nilotinib in adult patients with biomarker-enriched, recurrent malignant gliomas who have developed tumor progression after standard therapy. Patients will be treated with oral nilotinib (starting with the labeled dose of 400 mg) daily until disease progression or intolerance. One cycle is defined as 28 days.

Approximately 50 evaluable patients will be enrolled in this study, with 32 (grade IV) and 18 (grade III) in separate arms.

All patients will undergo clinical evaluation after each 28-day cycle. Neuroimaging studies (MRI) will be performed at baseline, 4 weeks, 8 weeks and then after every 2 cycles (8 weeks). If a contraindication for MRI's exists, patients will undergo contrast-enhanced CT scans. Laboratory tests will be obtained weekly during the first 4 weeks, and then on days 1 and 15 of all subsequent cycles. Patients will remain on study medication unless they develop tumor progression or unacceptable toxicity.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Glioma
Intervention  ICMJE Drug: nilotinib
400mg po (orally) BID (twice daily)
Other Name: Tasigna
Study Arms  ICMJE Experimental: nilotinib
Patients will take nilotinib twice daily at the standard dose of 400mg taken by mouth twice a day until disease progression or development of unacceptable side effects.
Intervention: Drug: nilotinib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: October 29, 2018)
38
Original Estimated Enrollment  ICMJE
 (submitted: June 8, 2010)
50
Actual Study Completion Date  ICMJE January 31, 2018
Actual Primary Completion Date October 5, 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Ability to provide written informed consent prior to participation in the study and any related procedures being performed.
  • Participants must have agreed to and signed an authorization for the release of their protected health information.
  • Subjects must be able to adhere to the dosing and visit schedules, and agree to record medication times accurately and consistently in a daily diary.
  • Participants must have a life expectancy of at least 8 weeks.
  • Patients greater than 18 years of age.
  • Histologically documented diagnosis of proven glioblastoma (GBM), or anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), and anaplastic mixed oligoastrocytoma (AMO). Patients are eligible if the original local pathology was lower-grade glioma. Pathology will be read centrally to confirm diagnosis.
  • Documentation of amplified PDGFRA by fluorescent in-situ hybridization (FISH), colorimetric in-situ hybridization (CISH), or quantitative PCR from tumor tissue (=>3 copy number). Availability of unstained paraffin slides or the paraffin block of pretreatment baseline tissue is required for eligibility and for molecular analysis and would help to identify molecular predictors of outcome (all patients).
  • Participants must have a Karnofsky Performance Status (KPS) ≥ 60.
  • Adequate end organ function, defined as the following:

    • Hematology:

      • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
      • Platelet count ≥ 100 x 109/L
      • Hemoglobin ≥ 9.0 g/dL
      • White blood cell (WBC) count ≥ 3.0 x 109/L
    • Biochemistry:

      • AST/SGOT and ALT/SGPT ≤ 2.5 x institution's ULN
      • Total bilirubin ≤ 1.5 x institution's ULN
      • Serum creatinine ≤ 1.5 x institution's ULN or 24-hour creatinine clearance ≥ 50 ml/min
      • Alkaline phosphatase (ALP) ≤ 2.5 x ULN unless considered tumor related
  • Patients must have the following laboratory values within normal limits (WNL) at the local institution lab or corrected to WNL with supplements prior to first dose of study medication.

    • Potassium (WNL)
    • Magnesium (WNL)
    • Phosphorous (WNL)
    • Calcium (WNL)
    • Coagulation studies:

      • INR < 1.5
      • PTT within institution's normal range, unless receiving therapeutic low molecular weight heparin
  • Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug.
  • Participants must have an unequivocal progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan. A scan must be performed within 14 days prior to registration and on a steroid dose that has been stable for at least 5 days. If the steroid dose is increased between the date of imaging and registration, a new baseline MRI/CT is required. The same type of scan, i.e., MRI or CT must be used throughout the period of protocol treatment for tumor measurement. A patient who develops a contraindication to undergo an MRI scan during study treatment may remain on study and undergo contrast enhanced CT scans.
  • Patients must have failed prior radiation therapy and must have an interval of greater than or equal to 60 days from the completion of radiation therapy to study entry.
  • Subjects must have recovered from the toxic effects of prior therapy. Residual toxicity from any previous treatment must be ≤ Grade 1.
  • Patients must have sufficient time for recovery from prior therapy: 28 days from any investigational agent, 28 days from prior cytotoxic therapy (except 23 days from prior temozolomide, 14 days from vincristine, 42 days from nitrosoureas, 21 days from procarbazine administration), and 7 days for non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. (radiosensitizer does not count).
  • Patients with prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease rather than radiation necrosis based upon positron emission tomography (PET), Thallium scanning, MR spectroscopy or surgical documentation of disease.
  • Subjects who have undergone recent resection of recurrent or progressive tumor will be eligible as long as all of the following conditions apply:

    • Prior to initiating therapy, 4 weeks must have elapsed since surgery;
    • Subjects must have recovered from surgical-related trauma;
    • Wound healing needs to have occurred.

Exclusion Criteria:

  • Patients who received PDGFR inhibitors (imatinib, sunitinib, nilotinib, etc.) previously are excluded (patients who received PDGFR antibody based treatment however are allowed).
  • History of intratumoral or peritumoral hemorrhage if deemed significant by the treating physician.
  • For patients requiring anticoagulation therapy, only therapeutic low molecular weight heparin or factor Xa inhibitors are permitted.
  • Due to the potential interaction between nilotinib and enzyme-inducing anti-epileptic drugs (EIAED), only patients on non-enzyme inducing anti-epileptic drugs (NEIAED) or on no anti-epileptic drugs are eligible.
  • Patient is < 3 years free of another primary malignancy except: if the other primary malignancy is not currently clinically neither significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed.
  • Female patients who are pregnant or breast-feeding, or intends to become pregnant during the study.
  • Any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy.
  • Patient has a rare hereditary problem of galactose intolerance, severe lactase deficiency or of glucose-galactose malabsorption.
  • Patients with any disease that will obscure toxicity or dangerously alter drug metabolism.
  • Patient with electrolyte abnormality (e.g., hypokalemia, hypomagnesemia, hypophosphatemia, hyperkalemia, hypocalcemia, hyponatremia) unless the level can be corrected to normal levels prior to initiating study drug.
  • Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.
  • Patient received chemotherapy within 4 weeks (6 weeks for nitrosourea) prior to study entry, unless the disease is rapidly progressing.
  • Concomitant use of any anti-cancer therapy or radiation therapy, or any other investigational agent.
  • Impaired cardiac function including any of the following:

    • Congenital long QT syndrome or a known family history of long QT syndrome;
    • History or presence of clinically significant ventricular or atrial tachyarrhythmias
    • Clinically significant resting bradycardia (< 50 beats per minute)
    • Inability to monitor the QT interval by ECG
    • QTc > 450 msec on baseline ECG. If QTc > 450 and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc
    • Myocardial infarction within 1 year of starting study drug
    • Other clinically significant heart disease (e.g., unstable angina, congestive heart failure, or uncontrolled hypertension)
  • Patients currently receiving treatment with strong CYP3A4 inhibitors and treatment cannot be either discontinued or switched to a different medication prior to starting study drug. See link for complete list of CYP3A4 inhibitors (http://medicine.iupui.edu/clinpharm/ddis/table.asp)
  • Patient currently receiving treatment with any medications that have the potential to prolong the QT interval and cannot be either discontinued or switched to a different medication prior to starting study drug. See link for a comprehensive list of agents that prolong the QT interval (http://www.azcert.org/medical-pros/drug-lists/printable-drug-list.cfm).
  • Impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection or gastric bypass surgery).
  • Acute or chronic pancreatic disease.
  • Another malignancy that is clinically significant or requires active intervention (chemotherapy or radiation)
  • Severe or uncontrolled medical conditions (i.e., uncontrolled diabetes, active or uncontrolled infection).
  • Acute or chronic liver or severe renal disease
  • History of significant congenital or acquired bleeding disorder.
  • Major surgery within 4 weeks prior to Day 1 of study or who have not recovered from prior surgery.
  • Treatment with other investigational agents within 30 days of Day 1.
  • History of non-compliance to medical regimens or inability to grant consent.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01140568
Other Study ID Numbers  ICMJE 091728
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party David Piccioni, M.D., Ph.D, University of California, San Diego
Study Sponsor  ICMJE David Piccioni, M.D., Ph.D
Collaborators  ICMJE Novartis
Investigators  ICMJE
Principal Investigator: David Piccioni, MD, PhD University of California Medical Center
PRS Account University of California, San Diego
Verification Date October 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP